Summit Therapeutics SMMT Payments to Akeso for upfront milestone payments
Discontinued — last reported Q4 '25
Payments to Akeso for upfront milestone payments at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept smmt:PaymentsForCollaborativeArrangement.
The official record: Summit Therapeutics’s 10-K, filed February 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's payments to akeso for upfront milestone payments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's payments to akeso for upfront milestone payments?
- Summit Therapeutics (SMMT) reported payments to akeso for upfront milestone payments of $0 in Q4 2025.
- What does payments to akeso for upfront milestone payments mean?
- Cash paid to partners for licensing or development milestones.
- How do you interpret payments to akeso for upfront milestone payments?
- Higher payments indicate aggressive pipeline expansion or high-value licensing deals, while lower payments suggest a focus on internal R&D or a lack of new partnership activity.
- How does payments to akeso for upfront milestone payments compare across companies?
- Common in biotech firms utilizing in-licensing strategies; peers often disclose these as 'upfront payments' or 'milestone payments' in the investing section.